Michael R Gold1, Torsten Sommer2, Juerg Schwitter3, Ahmed Al Fagih4, Timothy Albert5, Béla Merkely6, Michael Peterson7, Allen Ciuffo8, Sung Lee9, Lynn Landborg10, Jeffrey Cerkvenik10, Emanuel Kanal11. 1. Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina. Electronic address: goldmr@musc.edu. 2. Department of Diagnostic and Interventional Radiology and Nuclear Medicine, German Red Cross Hospital, Neuwied, Germany. 3. Department of CMR, University Hospital Lausanne, Lausanne, Switzerland. 4. Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. 5. Central Coast Cardiology, Salinas, California. 6. Heart Center Semmelweis University, Budapest, Hungary. 7. United Heart and Vascular Clinic, Minneapolis, Minnesota. 8. Sentara Norfolk General Hospital, Norfolk, Virginia. 9. Washington Hospital Center, Washington, DC. 10. Medtronic, Minneapolis, Minnesota. 11. Department of Radiology of Neuroradiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND:Magnetic resonance imaging (MRI) of patients withconventional implantable cardioverter-defibrillators (ICD) is contraindicated. OBJECTIVES: This multicenter, randomized trial evaluated safety and efficacy of a novel ICD system specially designed for full-body MRI without restrictions on heart rate or pacing dependency. The primary safety objective was >90% freedom from MRI-related events composite endpoint within 30 days post-MRI. The primary efficacy endpoints were ventricular pacing capture threshold and ventricular sensing amplitude. METHODS: Subjects received either a single- or dual-chamber ICD. In a 2:1 randomization, subjects either underwent MRI at 1.5-T of the chest, cervical, and head regions to maximize radiofrequency exposure up to 2 W/kg specific absorption rate and gradient field exposure to 200 T/m/s per axis (MRI group, n = 175), or they underwent a 1-h waiting period without MRI (control group, n = 88). A subset of MRI patients underwent ventricular fibrillation induction testing post-MRI to characterize defibrillation function. RESULTS:In 42 centers, 275 patients were enrolled (76% male, age 60.4 ± 13.8 years). The safety endpoint was met with 100% freedom from the composite endpoint (p < 0.0001). Both efficacy endpoints were met with minimal differences in the proportion of MRI and control patients who demonstrated a ≤0.5 V increase in ventricular pacing capture threshold (100% MRI vs. 98.8% control, noninferiority p < 0.0001) or a ≤50% decrease in R-wave amplitude (99.3% MRI vs. 98.8% control, noninferiority p = 0.0001). A total of 34 ventricular tachyarrhythmia/ventricular fibrillation episodes (20 induced; 14 spontaneous) occurred in 24 subjects post-MRI, with no observed effect on sensing, detection, or treatment. CONCLUSIONS: This is the first randomized clinical study of an ICD system designed for full-body MRI at 1.5-T. These data support that the system is safe and the MRI scan does not adversely affect electrical performance or efficacy. (Confirmatory Clinical Trial of the Evera MRI System for Conditionally-Safe MRI Access; NCT02117414).
RCT Entities:
BACKGROUND: Magnetic resonance imaging (MRI) of patients with conventional implantable cardioverter-defibrillators (ICD) is contraindicated. OBJECTIVES: This multicenter, randomized trial evaluated safety and efficacy of a novel ICD system specially designed for full-body MRI without restrictions on heart rate or pacing dependency. The primary safety objective was >90% freedom from MRI-related events composite endpoint within 30 days post-MRI. The primary efficacy endpoints were ventricular pacing capture threshold and ventricular sensing amplitude. METHODS: Subjects received either a single- or dual-chamber ICD. In a 2:1 randomization, subjects either underwent MRI at 1.5-T of the chest, cervical, and head regions to maximize radiofrequency exposure up to 2 W/kg specific absorption rate and gradient field exposure to 200 T/m/s per axis (MRI group, n = 175), or they underwent a 1-h waiting period without MRI (control group, n = 88). A subset of MRI patients underwent ventricular fibrillation induction testing post-MRI to characterize defibrillation function. RESULTS: In 42 centers, 275 patients were enrolled (76% male, age 60.4 ± 13.8 years). The safety endpoint was met with 100% freedom from the composite endpoint (p < 0.0001). Both efficacy endpoints were met with minimal differences in the proportion of MRI and control patients who demonstrated a ≤0.5 V increase in ventricular pacing capture threshold (100% MRI vs. 98.8% control, noninferiority p < 0.0001) or a ≤50% decrease in R-wave amplitude (99.3% MRI vs. 98.8% control, noninferiority p = 0.0001). A total of 34 ventricular tachyarrhythmia/ventricular fibrillation episodes (20 induced; 14 spontaneous) occurred in 24 subjects post-MRI, with no observed effect on sensing, detection, or treatment. CONCLUSIONS: This is the first randomized clinical study of an ICD system designed for full-body MRI at 1.5-T. These data support that the system is safe and the MRI scan does not adversely affect electrical performance or efficacy. (Confirmatory Clinical Trial of the Evera MRI System for Conditionally-Safe MRI Access; NCT02117414).
Authors: Carol Chen-Scarabelli; Chad McRee; Massoud A Leesar; Fadi G Hage; Tiziano M Scarabelli Journal: J Nucl Cardiol Date: 2016-05-25 Impact factor: 5.952
Authors: Rainer Zbinden; Christian Wollmann; Johannes Brachmann; Jochen Michaelsen; Clemens Steinwender; Pramesh Kovoor; Sebastian Kelle; Andrew D McGavigan; Chi Keong Ching; Gemma A Figtree; Jan Schmidt; Tobias Timmel; Joachim Lotz Journal: Europace Date: 2019-11-01 Impact factor: 5.214
Authors: Steven Mullane; Kyle Michaelis; Charles Henrikson; Sei Iwai; Crystal Miller; Camden Harrell; David Hayes Journal: Heart Rhythm O2 Date: 2021-03-09
Authors: Wolfgang Rudolf Bauer; Dennis H Lau; Christian Wollmann; Andrew McGavigan; Jacques Mansourati; Theresa Reiter; Simone Frömer; Mark E Ladd; Harald H Quick Journal: Sci Rep Date: 2019-12-03 Impact factor: 4.379